Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

NCT03954743 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1351

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Rotavirus

Interventions

BIOLOGICAL: PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine
BIOLOGICAL: Lyophilized formulation of GSK's oral live attenuated HRV vaccine

Sponsor

GlaxoSmithKline